US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

ABPRO HOLDINGS INC

us-stock
To Invest in {{usstockname}}
us-stock
$5.76 -0.0379(-3.79%) ABP at 09 Dec 2025 05:36 PM Biotechnology
Lowest Today 5.57
Highest Today 5.68
Today’s Open 5.68
Prev. Close 5.81
52 Week High 147.70
52 Week Low 4.63
Day’s Range: Low 5.57 High 5.68
52-Week Range: Low 4.63 High 147.70
1 day return -
1 Week return +2.42
1 month return -3.85
3 month return +3121.63
6 month return +2116.82
1 year return +230.12
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 15.78 M

PB Ratio 0.0

PE Ratio 0.0

Enterprise Value 15.60 M

Total Assets 4.66 M

Volume 16052

Company Financials

Fund house & investment objective

Company Information Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO Mr. Jin Wook Suk

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right